CompletedPhase 4NCT00707850

Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection

Studying Thalassemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Baqiyatallah Medical Sciences University
Principal Investigator
Seyed-Moayed Alavian, Professor
Baqiyatallah Research Center for Gastroenterology and Liver Disea
Intervention
PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)(drug)
Enrollment
300 target
Eligibility
12 years · All sexes
Timeline
20072009

Study locations (1)

Collaborators

Baqiyatallah Research Center for Gastroenterology and Liver Diseases · Tehran Hepatitis Center · Guilan University of Medical Sciences · Tabriz Research Center for Gastroenterology and Liver Diseases

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00707850 on ClinicalTrials.gov

Other trials for Thalassemia

Additional recruiting or active studies for the same condition.

See all trials for Thalassemia

← Back to all trials